Share on StockTwits

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) were the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 12,858,783 shares, a drop of 6.9% from the July 15th total of 13,809,803 shares, Stock Ratings Network.com reports. Based on an average trading volume of 968,566 shares, the days-to-cover ratio is presently 13.3 days. Currently, 25.9% of the company’s stock are sold short.

A number of research firms have recently commented on AUXL. Analysts at RBC Capital cut their price target on shares of Auxilium Pharmaceuticals from $32.00 to $28.00 in a research note on Friday, August 8th. They now have an “outperform” rating on the stock. Separately, analysts at Aegis cut their price target on shares of Auxilium Pharmaceuticals to $34.00 in a research note on Thursday, August 7th. They noted that the move was a valuation call. Finally, analysts at Aegis initiated coverage on shares of Auxilium Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $37.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $26.92.

Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 17.64 on Wednesday. Auxilium Pharmaceuticals has a one year low of $16.36 and a one year high of $32.89. The stock has a 50-day moving average of $19. and a 200-day moving average of $23.8. The company’s market cap is $886.5 million.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last released its earnings data on Thursday, August 7th. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.64 by $2.08. The company had revenue of $83.00 million for the quarter, compared to the consensus estimate of $482.80 million. During the same quarter in the prior year, the company posted $0.22 earnings per share. The company’s quarterly revenue was down 17.4% on a year-over-year basis. Analysts expect that Auxilium Pharmaceuticals will post $-0.41 EPS for the current fiscal year.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.